All In Biotech

Drug Trial Radar · NCT00340834

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

A 12-month Double-blind, Randomized, Multicenter, Active-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon ß-1a (Avonex) Administered im Once Weekly in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase

Last checked: Nov 20, 2026Latest source record: Sep 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,292 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,292

Actual

Start

May 2006

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Jun 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • Fingolimod 1.25 mgDrug

    Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

  • Fingolimod 0.5 mgDrug

    Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly. Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily.

  • Interferon β-1a 30 µgDrug

    Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily. Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the StudyTime frame: Baseline to Month 12

Locations

170 sites in 18 countries. Site status is shown where the registry gives one.

  • North Central Neurology Associates, PC, 1809 Kress Street

    Cullman, Alabama

  • Barrow Neurological Institute

    Phoenix, Arizona

  • The Neurology Center, 3907 Waring Road, Suite 3

    Oceanside, California

  • Associated Neurologists, PC, 69 Sand Pit Road, Suite 300

    Danbury, Connecticut

  • Associated Neurologists of Southern CT, PC, 75 Kings Highway Cutoff

    Fairfield, Connecticut

  • Yale University Multiple Sclerosis Center

    New Haven, Connecticut

  • University of Florida Health Science Center

    Jacksonville, Florida

  • Neurology Associates, PA, 301 N. Maitland Avenue, Suite A1

    Maitland, Florida

  • University of Miami, Department of Neurology

    Miami, Florida

  • Neurological Associates

    Pompano Beach, Florida

  • Roskamp Institute, 2040 Whitfield Ave.

    Sarasota, Florida

  • AMO Corporation

    Tallahassee, Florida

  • Axiom Clinical Research of Florida, 2919 Swann Avenue, Suite 401

    Tampa, Florida

  • University of South Florida, Department of Neurology

    Tampa, Florida

  • The MS Center of Vero Beach

    Vero Beach, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Mid America Neuroscience Institute, 8550 Marshall Drive, Suite 100

    Lenexa, Kansas

  • University Physician Group, #1 Barnes-Jewish Hospital Plaza, Suite 16304

    St Louis, Missouri

  • Neuroscience and Spine Center

    Charlotte, North Carolina

  • Raleigh Neurology Associates, 1540 Sunday Drive

    Raleigh, North Carolina

  • Neurology & Neuroscience Associates, Inc

    Akron, Ohio

  • Northern Ohio Neuroscience, LLC

    Bellevue, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Oregon Neurology

    Tualatin, Oregon

  • University of Pittsburgh, Department of Neurology

    Pittsburgh, Pennsylvania

  • Absher Neurology, 274-A Commonwealth Drive

    Greenville, South Carolina

  • Mountain Empire Neurological Associates, PC, 3183 West State Street, Suite 1201

    Bristol, Tennessee

  • Advanced Neurosciences Institute

    Franklin, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Private Practice, 3815 23rd Street

    Lubbock, Texas

  • Integra Clinical Research, 4242 Medical Drive, Suite 6100

    San Antonio, Texas

  • Swedish Neuroscience Institute

    Seattle, Washington

  • Rockwood Clinic, P.S.

    Spokane, Washington

  • West Virginia University Health Associates

    Morgantown, West Virginia

  • Center for Neurological Disorders - Aurora St. Luke's Med Center

    Milwaukee, Wisconsin

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Fundacion Lenox Cordoba

    Córdoba, Argentina

  • Hospital J. M. Ramos Mejia

    General Urquiza 609, Buenos Aires, Argentina

  • FLENI

    Montaneses 2325, Buenos Aires, Argentina

  • Ineba

    Guarda Vieja 4435, Capital Federal, Buenos Aires, Argentina

Showing 40 of 170 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.